液态活检对肝癌肝移植术后复发预测的研究进展  

Research progress of liquid biopsy for predicting recurrence in patients with hepatocellular carcinoma after liver transplantation

作　　者：王瑞涛[1] Wang Ruitao(Department of Hepatobiliary Surgery,the First Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710061,China)

机构地区：[1]西安交通大学第一附属医院肝胆外科,710061

出　　处：《中华移植杂志（电子版）》2021年第3期189-192,共4页Chinese Journal of Transplantation(Electronic Edition)

基　　金：陕西省提升公众科学素质计划项目[2020PSL(Y)044];陕西省重点研发计划项目(2019SF-007)。

摘　　要：肝移植是目前治疗原发性肝癌的有效方法,然而肝癌肝移植术后复发极大地影响了受者生存,探索肝癌肝移植术后复发相关标志物,筛选高危人群,早期预警,是防治肝癌复发的主要目标。目前针对肝癌肝移植术后复发影响因素的研究主要集中在移植手术前后临床因素的影响以及基于生物标志物对复发的预测。前者已有大量且详实的研究报道;后者随着生物科技的发展已成为目前关注的重点及热点,其中基于体液样本的非侵入性检测,即液态活检是极具前景的诊断方法,在肝癌肝移植术后复发预测方面受到广泛关注。本文针对近年来液态活检在肝癌肝移植术后复发预测方面的研究进展进行综述。Liver transplantation is an effective method for the treatment of primary liver cancer.However,liver cancer recurrence after liver transplantation greatly affects survival of patients.The main goals of prevention and treatment of liver cancer recurrence are to explore recurrence markers after liver transplantation,screen high-risk recurrence groups and provide early warning signs.At present,studies on recurrence factors of liver transplantation mainly focus on two aspects:preoperative and postoperative clinical factors which have many detailed research reports;predictability of recurrence based on biomarkers.With the development of biotechnology,predictability of biomarkers has become hotspot on liver cancer recurrence after liver transplantation.Therefore,the non-invasive test based on body fluid samples,named liquid biopsy,is a promising marker and has been widely concerned in the prediction of recurrence after liver transplantation.Our review summarizes the recent studies of liquid biopsy on the prediction of liver cancer recurrence after liver transplantation.

关 键 词：液态活检 肝细胞肝癌 肝移植 复发预测 

分 类 号：R735.7[医药卫生—肿瘤]